Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue: early-phase trial registry
1 of 3 indexed Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue: 3 US clinical trials tracked, 1 recruiting.
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-extranodal-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue
OPEN 1 | RECR 33% | LATE 0 | EARLY 3 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT06859008
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
NCT02339922
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT05169658
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue condition card totals 3 registered trials; most-linked intervention Computed Tomography; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.